Business
ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023
LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will
About this update from Niagen Bioscience, Inc.
[{"type":"text","content":" LOS ANGELES--(BUSINESS WIRE)--\nChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 8, 2023 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year, which ended December 31, 2022. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.\n\nInvestor Conference Call:\n\nChromaDex management will host an investor conference call to discuss fourth quarter and fiscal year 2022 results and provide a general business update on Wednesday, March 8, at 4:30 p.m. ET.\n\nParticipants should call in at least 10 minutes prior to the call. The dial-in information is as follows:\n\nDate: Wednesday, March 8, 2023\nTime: 4:30 p.m. ET (1:30 p.m. PT)\nToll-free dial-in number: 1-888-330-2446\nConference ID: 4126168\nWebcast link: ChromaDex Fourth Quarter 2022 Earnings Conference Call\n\nThe conference call will be broadcast live and available for replay here and via the investor relations section of the Company’s website at www.chromadex.com.\n\nA replay of the conference call will be available from 7:30 p.m. ET on March 8, 2023, to 11:59 p.m. ET on March 14, 2023.\n\nToll-free replay number: 1-800-770-2030\nReplay ID: 4126168\n\nAbout ChromaDex:\n\nChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.\n\nImportant Note on Forward Looking Statements:\n\nThis release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-lookin...